Pharmaceutical - Pharmaceutical, Gastro-intestinals

Filter

Popular Filters

1 to 25 of 159 results

Anthera appoints Chuck Olson as president of Alkira

Anthera appoints Chuck Olson as president of Alkira

15-07-2014

US-based biopharma Anthera Pharmaceuticals has appointed Chuck Olson as president of its subsidiary Alkira…

Anthera PharmaceuticalsBoardroomBusiness FinanceBusiness FinanceGastro-intestinalsHealth Medical PharmaPancreasPharmaceuticalProduct manufacturingUSA

Astellas submits sNDA for Irribow/Irribow OD in Japan

Astellas submits sNDA for Irribow/Irribow OD in Japan

14-07-2014

Japanese drug major Astellas Pharma has submitted a supplemental New Drug Application for the indication…

Astellas PharmaGastro-intestinalsIrribowJapanPharmaceuticalRegulation

Salix Pharma to combine with unit of Italy’s Cosmo

Salix Pharma to combine with unit of Italy’s Cosmo

09-07-2014

US drugmaker Salix Pharmaceuticals has agreed to combine with an Ireland-based unit of Italy’s Cosmo…

Cosmo PharmaceuticalsCosmo TechnologiesGastro-intestinalsMergers & AcquisitionsPharmaceuticalSalix Pharmaceuticals

Swissmedic approves Amitiza for opioid-induced constipation

Swissmedic approves Amitiza for opioid-induced constipation

08-07-2014

US biopharma firm Sucampo Pharmaceuticals has received approval from Swissmedic, Switzerland’s Agency…

AmitizaEuropeGastro-intestinalsPharmaceuticalRegulationSucampo

Salix leaps on positive Ph III results with Xifaxan in IBS-D

Salix leaps on positive Ph III results with Xifaxan in IBS-D

02-07-2014

US drugmaker Salix Pharmaceuticals’ saw its shares leap as much as 13% after the company released new…

Gastro-intestinalsPharmaceuticalResearchrifaximinSalix PharmaceuticalsXifaxan

UK’s NICE recommends Sucampo’s Amitiza for CIC

UK’s NICE recommends Sucampo’s Amitiza for CIC

18-06-2014

The UK health care watchdog the National Institute of Health and Care Excellence (NICE) has released…

AmitizaGastro-intestinalsPharmaceuticalPricingRegulationSucampoUK

Takelda combination tablets now available in Japan

Takelda combination tablets now available in Japan

13-06-2014

Japan’s largest drugmaker Takeda Pharmaceutical says that Takelda, a fixed-dose combination (FDC) of…

Gastro-intestinalsJapanMarkets & MarketingPharmaceuticalTakeda PharmaceuticalTakelda

Positive US FDA advisory panel view on PAMORAs

Positive US FDA advisory panel view on PAMORAs

13-06-2014

The majority of US Food and Drug Administration Anesthetic and Analgesic Drug Products Advisory Committee…

AstraZenecaGastro-intestinalsMovantiknaloxegolPharmaceuticalRegulationUSA

Approval of Takeda’s Entyvio marks “historic change” for IBD treatment

Approval of Takeda’s Entyvio marks “historic change” for IBD treatment

03-06-2014

The recent approval of Japanese drug major Takeda’s Entyvio (vedolizumab) by the European Medicines…

EntyvioGastro-intestinalsHumiraMarkets & MarketingPharmaceuticalRemicadeSimponi InjectionStelaraTakeda Pharmaceutical

EU approval for Takeda’s Entyvio for UC and Crohn’s disease

27-05-2014

Takeda Pharmaceutical, Japan’s largest drugmaker has received marketing approval from the European…

EntyvioEuropeGastro-intestinalsPharmaceuticalRegulationTakeda Pharmaceutical

US FDA thumbs up for Takeda’s Entyvio for ulcerative colitis and Crohn's disease

US FDA thumbs up for Takeda’s Entyvio for ulcerative colitis and Crohn's disease

21-05-2014

The US Food and Drug Administration yesterday approved Entyvio (vedolizumab) injection, from Japan’s…

EntyvioGastro-intestinalsPharmaceuticalRegulationTakeda PharmaceuticalsUSA

Forest Labs to acquire Furiex Pharma in $1.46 billion deal

29-04-2014

US drugmaker Forest Laboratories has entered into a definitive agreement to acquire Furiex Pharmaceuticals…

eluxadolineForest LaboratoriesFuriex PharmaceuticalsGastro-intestinalsMergers & AcquisitionsPharmaceuticalRoyalty Pharma

Almirall gains European rights to InDex Pharma’s Kappaproct

07-04-2014

Sweden’s InDex Pharmaceuticals and Spain’s largest drugmaker Almirall have signed a license agreement…

AlmirallEuropeGastro-intestinalsInDex PharmaceuticalsKappaproctLicensingPharmaceutical

Generic pains for AstraZeneca exacerbated by Indian drugmakers

Generic pains for AstraZeneca exacerbated by Indian drugmakers

06-04-2014

Indian generic companies are taking aim at mega blockbusters, and AstraZeneca, the $25.7 billion pharmaceutical…

Asia-PacificAstraZenecaDr Reddy's LaboratoriesFinancialGastro-intestinalsGenericsIndiaMarkets & MarketingNexiumPharmaceuticalPulmicortRanbaxy LaboratoriesRespiratory and PulmonarySymbicortUSAVimovo

Otsuka and Takeda to co-promote TAK-438 in the GI therapy area in Japan

Otsuka and Takeda to co-promote TAK-438 in the GI therapy area in Japan

29-03-2014

Japanese drugmakers Otsuka Pharmaceutical and Takeda Pharmaceutical have entered into a co-promotion…

Asia-PacificGastro-intestinalsJapanLicensingMarkets & MarketingOtsukaPharmaceuticalTAK-438Takeda Pharmaceuticalsvonoprazan

Takeda gets positive CHMP opinion for Entyvio for UC and Crohn’s disease

21-03-2014

Takeda Pharmaceutical, Japan’s largest drugmaker, today received a positive opinion form the European…

EntyvioEuropeGastro-intestinalsPharmaceuticalRegulationTakeda Pharmaceuticals

Latest Australian PBS Listings include medicines for children

Latest Australian PBS Listings include medicines for children

19-03-2014

Ten new medicines to treat a range of illnesses from rare forms of cancer to skin conditions will be…

Anti-Arthritics/RheumaticsAsia-PacificAustraliaDermatologicalsDiabetesGastro-intestinalsHealthcareOncologyPharmaceuticalPricing

Sanofi and UCB in immune-mediated diseases research partnership

Sanofi and UCB in immune-mediated diseases research partnership

11-03-2014

French pharma major Sanofi and UCB, Belgium’s largest drugmaker, have entered into a scientific and…

Anti-Arthritics/RheumaticsGastro-intestinalsImmunologicalsPharmaceuticalResearchSanofiUCB

Highlights from the Pharmacovigilance Risk Assessment Committee meeting

Highlights from the Pharmacovigilance Risk Assessment Committee meeting

09-03-2014

The European Medicines Agency's Pharmacovigilance Risk Assessment Committee (PRAC) gave recommendations…

diacereindomperidoneEuropeGastro-intestinalsNeurologicalPharmaceuticalRegulationzolpidem

Global ulcerative colitis market to reach $6.6 billion by 2022

Global ulcerative colitis market to reach $6.6 billion by 2022

14-02-2014

The global ulcerative colitis market value will increase steadily over the coming years, increasing from…

AbbVieEntyvioGastro-intestinalsGlobalHumiraJohnson & JohnsonMarkets & MarketingPharmaceuticalRemicadeSimponi InjectionTakeda Pharmaceuticals

Furiex shares double after top-line results of IBS drug eluxadoline in two Phase III studies

Furiex shares double after top-line results of IBS drug eluxadoline in two Phase III studies

05-02-2014

Furiex Pharmaceuticals has announced top-line results from two pivotal Phase III clinical trials evaluating…

FinancialFuriex PharmaceuticalsGastro-intestinalsPharmaceuticalResearchUSA

Modest growth forecast for global Crohn’s disease market

Modest growth forecast for global Crohn’s disease market

04-02-2014

The global Crohn’s disease (CD) market value is forecast to show modest growth, climbing from $3.2…

AbbVieBiotechnologyEntyvioGastro-intestinalsGlobalHumiraJohnson & JohnsonMarkets & MarketingPharmaceuticalRemicadeStelara InjectionTakeda Pharmaceuticals

Promising late-stage GI drugs could stabilize global market decline; report

16-01-2014

The gastrointestinal (GI) therapeutics market for irritable bowel syndrome (IBS), ulcerative colitis…

BiosimilarsGastro-intestinalsGlobalMarkets & MarketingPharmaceuticalRemicadeTakeda Pharmaceuticalsvedolizumab

Astellas and UMN update on Ph III trials of flu vaccine ASP7374; debuts Irribow OD in Japan

Astellas and UMN update on Ph III trials of flu vaccine ASP7374; debuts Irribow OD in Japan

15-01-2014

Japanese drug major Astellas Pharma and partner UMN Pharma have announced promising summary results for…

Asia-PacificASP7374Astellas PharmaGastro-intestinalsIrribowMarkets & MarketingPharmaceuticalResearchUMN PharmaVaccines

1 to 25 of 159 results

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top